VanEck Biotech ETF (NASDAQ:BBH) Shares Sold by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lowered its holdings in VanEck Biotech ETF (NASDAQ:BBH) by 86.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 247 shares of the company’s stock after selling 1,625 shares during the period. Tower Research Capital LLC TRC’s holdings in VanEck Biotech ETF were worth $41,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. CIBC Private Wealth Group LLC acquired a new stake in VanEck Biotech ETF during the 4th quarter valued at $572,000. Condor Capital Management acquired a new stake in VanEck Biotech ETF during the 4th quarter valued at $800,000. Focus Financial Network Inc. ADV acquired a new stake in VanEck Biotech ETF during the 4th quarter valued at $2,328,000. Pine Valley Investments Ltd Liability Co grew its holdings in VanEck Biotech ETF by 13.2% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 2,150 shares of the company’s stock valued at $355,000 after purchasing an additional 250 shares in the last quarter. Finally, Tidemark LLC acquired a new stake in VanEck Biotech ETF during the 4th quarter valued at $34,000. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

BBH traded up $1.92 during trading hours on Thursday, reaching $160.56. 4,133 shares of the stock traded hands, compared to its average volume of 8,823. The firm’s fifty day simple moving average is $161.83 and its two-hundred day simple moving average is $159.77. VanEck Biotech ETF has a fifty-two week low of $142.51 and a fifty-two week high of $171.04.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.